Information for the public
Other guidance
NICE guidance
-
Hepatitis B and C: ways to promote and offer testing. NICE public health guidance 43 (2012). See http://guidance.nice.org.uk/PH43
-
Patient experience in adult NHS services. NICE clinical guideline 138 (2012). See http://guidance.nice.org.uk/CG138.
-
Medicines adherence. NICE clinical guideline 76 (2009). See http://guidance.nice.org.uk/CG76
-
Reducing differences in the uptake of immunisations. NICE public health guidance 21 (2009). See http://guidance.nice.org.uk/PH21
-
Hepatitis B – tenofovir disoproxil fumarate. NICE technology appraisal guidance 173 (2009). See http://guidance.nice.org.uk/TA173
-
Hepatitis B – telbivudine. NICE technology appraisal guidance 154 (2008). See http://guidance.nice.org.uk/TA154
-
Hepatitis B – entecavir. NICE technology appraisal guidance 153 (2008). See http://guidance.nice.org.uk/TA153
-
Hepatitis B (chronic) – adefovir dipivoxil and pegylated interferon alfa‑2a. NICE technology appraisal guidance 96 (2006). See http://guidance.nice.org.uk/TA96
Other relevant guidance
-
Hepatitis B antenatal screening and newborn immunisation programme: Best practice guidance. Department of Health (2011). See https://www.gov.uk/government/publications/hepatitis-b-antenatal-screening-and-newborn-immunisation-programme-best-practice-guidance
-
The Green Book: Chapter 18 – Hepatitis B. Department of Health (2009). See: https://www.gov.uk/government/publications/hepatitis-b-the-green-book-chapter-18